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Extracts of Artemisia annua and related plants have been used for centuries to treat and prevent
malaria as well as other infectious diseases caused by parasites, viruses, and bacteria (1). The
identiﬁcation of the active pharmaceutical ingredient artemisinin eventually resulted in the
preparation of the semi-synthetic derivative artesunate that has a longer half-life and better
bioavailability when compared to artemisinin (2). Following the discovery that artemisinin and
its derivatives are active against a host of human cancer cell lines by Prof. Efferth in 2001 (3),
preclinical and clinical evidence has been obtained to make a strong case for signiﬁcant anticancer
activity for artemisinin derivatives such as artesunate (4). However, the pharmacological challenges
such as short half-life and poor bioavailability may limit anticancer activity (5). In this Research
Topic, Kagan et al. report the development of 2-carbon-linked dimeric artemisinins (2C-ART) that
demonstrate low-nanomolar IC50s against multiple AML cell lines. The lead compound, ART631,
elevated ROS and induced apoptosis and was active in combination with sorafenib and venetoclax
in both cell models and xenografts. While ART631 is limited by less than optimal in vitro stability,
further optimization to improve efﬁcacy and stability are warranted.
A wide variety of anticancer mechanisms have been proposed for artemisinins, including
inducing apoptosis, cell cycle arrest, ferroptosis and inhibiting angiogenesis and invasion (4). While
multiple signaling pathways are implicated, few direct targets for artesunate are reported. Li et al. for
the ﬁrst time demonstrate that human telomerase reverse transcriptase (hTERT) is overexpressed in
esophageal cancer compared to adjacent normal tissue and correlated with poor prognosis. They
also demonstrate that dihydroartemisinin (DHA), which is a semi-synthetic derivative of
artemisinin, reduces proliferation of esophageal cancer cells and down regulates hTERT
expression at the transcriptional level via interaction and down regulation of the transcription
factor SP1. DHA also reduced tumor volumes in xenograft models. This is a novel mechanism of
action for DHA, which may help guide further study into synergistic combinations for the treatment
of esophageal cancer.
Yi et al. have also identiﬁed a novel mechanism of DHA activity in colon cancer. RNA seq
analysis between DHA treated and untreated cancer cells suggested overexpression of CDK1,
CCNB1 and PLK1, which was followed with molecular docking studies that suggest that DHA could
dock into the CDK1/CCNB1 complex resulting in cell cycle arrest in the G2/M phase and
suppressed CDK1/CCNB1/PLK1 signaling activation. While artemisinin derivatives are well
known to affect the cell cycle, this report is the ﬁrst to identify the CDK1/CCNB1 complex as a
potential target.
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This Research Topic provides insights into novel artemisinin
derivatives as well as proposes several new mechanisms of action
which we anticipate will help investigators in the ﬁeld advance their
studies. However, several key gaps in knowledge still exist. First, the
speciﬁc anticancer mechanism of artemisinins remains elusive,
with dozens of potential targets and mechanisms demonstrated
across a variety of cell lines. A unifying mechanism of action (or
disproval) still remains to be identiﬁed. Next, artemisinin
derivatives remain pharmacologically challenging compounds
with short in vivo half-lives and relatively low potency,
representing further opportunities for compound optimization.

Finally, identiﬁcation of mechanisms of artesunate resistance
remain in their infancy and are critical to the ultimate
development of these artemisinin derivatives as anticancer
agents (6).
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